Cytokinetics (NASDAQ:CYTK) Releases Quarterly Earnings Results, Beats Expectations By $0.13 EPS

Cytokinetics (NASDAQ:CYTK) posted its earnings results on Thursday. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.63) by $0.13, FiscalAI reports. The firm had revenue of $28.62 million for the quarter, compared to analyst estimates of $17.59 million. During the same period in the previous year, the company posted ($1.12) EPS. Cytokinetics’s revenue was down 57.1% on a year-over-year basis.

Here are the key takeaways from Cytokinetics’ conference call:

• MYQORZO launch momentum exceeded expectations, with $25.3 million in Q2 net product revenue, 1,500 patients dispensed, more than 700 U.S. prescribers, and greater than 40% exit share of new-to-brand prescriptions. Medicare coverage reached nearly 90% parity, while commercial coverage exceeded 50%.
• Aficamten’s ACACIA-HCM Phase III trial met both primary endpoints in non-obstructive HCM, improving KCCQ scores and peak VO2 without new safety signals. The company plans to submit a supplemental NDA for the nHCM indication in Q4 2026, potentially expanding MYQORZO to a substantially larger patient population.
• International expansion progressed with the German launch, U.K. marketing authorization and NICE reimbursement guidance, and reimbursement approval in the Netherlands. The company expects a U.K. launch later this year, followed by additional European launches through 2027.
• Cytokinetics ended Q2 with approximately $1.7 billion in cash and investments after raising $760 million, providing funding for commercialization and pipeline development. However, the net loss widened to $198.8 million, and full-year combined R&D and SG&A expense guidance was increased to $860 million–$890 million.
• The broader specialty-cardiology pipeline continued advancing, with COMET-HF enrolling more than one-third of patients, AMBER-HFpEF expected to complete its first cohort in the second half of 2026, and the adolescent cohort of CEDAR-HCM enrolling ahead of schedule.

Cytokinetics Price Performance

Shares of CYTK stock traded down $4.61 during midday trading on Friday, hitting $76.76. The company had a trading volume of 3,604,418 shares, compared to its average volume of 1,732,641. The company’s 50 day simple moving average is $78.91 and its 200 day simple moving average is $70.90. Cytokinetics has a 52-week low of $32.89 and a 52-week high of $88.31. The stock has a market cap of $9.55 billion, a price-to-earnings ratio of -10.63 and a beta of 0.38.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Myqorzo uptake is encouraging. Management and analysts highlighted strong early traction for Myqorzo, supporting the view that the drug could become an important commercial growth driver. CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong
• Positive Sentiment: Quarterly results exceeded expectations. Cytokinetics reported revenue of $28.6 million versus consensus estimates near $17.6 million and a loss of $1.50 per share, narrower than the expected $1.63 loss. Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts raised their targets. Needham increased its target from $102 to $112 and maintained a “buy” rating, while Citizens JMP raised its target from $105 to $110 and kept a “market outperform” rating. These actions indicate analysts see meaningful upside if the launch continues to perform. Analyst Price Target Updates
• Neutral Sentiment: The commercial launch is still early. RBC viewed the earnings beat as supportive of Myqorzo’s launch, but investors will likely focus on prescription growth, reimbursement and the pace at which sales offset launch expenses.
• Negative Sentiment: Profitability and cash flow remain major concerns. Revenue fell 57.1% year over year, while Cytokinetics posted a $179.2 million operating loss and used $159.8 million in operating cash during the quarter. Higher launch costs and the absence of milestone payments also weighed on results, despite the $1.17 billion cash balance. Cytokinetics Q2 2026 Earnings: Revenue Beats but Losses Persist
• Negative Sentiment: Reported losses widened from the prior-year quarter. The quarterly loss increased from $1.12 per share a year earlier to $1.50, underscoring that CYTK remains dependent on successful commercialization and future financing or milestone opportunities. Cytokinetics Reports Q2 Loss, Beats Revenue Estimates

Insider Buying and Selling

In other Cytokinetics news, CEO Robert I. Blum sold 7,500 shares of the business’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $80.87, for a total value of $606,525.00. Following the transaction, the chief executive officer directly owned 377,820 shares of the company’s stock, valued at approximately $30,554,303.40. The trade was a 1.95% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Callos sold 14,000 shares of the firm’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $79.88, for a total transaction of $1,118,320.00. Following the completion of the sale, the executive vice president owned 58,555 shares of the company’s stock, valued at $4,677,373.40. This trade represents a 19.30% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 115,179 shares of company stock worth $9,126,054 over the last three months. 2.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Cytokinetics

Institutional investors have recently made changes to their positions in the stock. Millennium Management LLC lifted its stake in shares of Cytokinetics by 361.9% in the first quarter. Millennium Management LLC now owns 287,901 shares of the biopharmaceutical company’s stock valued at $11,571,000 after purchasing an additional 225,576 shares during the period. Cetera Investment Advisers grew its position in Cytokinetics by 12.4% during the second quarter. Cetera Investment Advisers now owns 6,635 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 731 shares during the period. EverSource Wealth Advisors LLC grew its position in Cytokinetics by 723.7% during the second quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 673 shares during the period. Gabelli Funds LLC increased its holdings in Cytokinetics by 29.4% in the second quarter. Gabelli Funds LLC now owns 8,410 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 1,910 shares in the last quarter. Finally, California Public Employees Retirement System increased its holdings in Cytokinetics by 10.8% in the second quarter. California Public Employees Retirement System now owns 142,602 shares of the biopharmaceutical company’s stock valued at $4,712,000 after buying an additional 13,911 shares in the last quarter.

Analyst Ratings Changes

Several brokerages have recently issued reports on CYTK. JPMorgan Chase & Co. increased their price objective on Cytokinetics from $92.00 to $97.00 and gave the company an “overweight” rating in a research note on Tuesday, May 12th. Wall Street Zen lowered shares of Cytokinetics from a “hold” rating to a “sell” rating in a research note on Saturday. Mizuho boosted their price objective on Cytokinetics from $100.00 to $118.00 and gave the company an “outperform” rating in a research note on Wednesday, June 24th. HC Wainwright lifted their target price on shares of Cytokinetics from $136.00 to $140.00 and gave the company a “buy” rating in a report on Monday, May 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cytokinetics in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $100.85.

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.